The size of Taiwan Over the Counter (OTC) Drugs Market was worth USD 1.90 billion in 2022 and estimated to reach USD 2.53 billion by the end of 2027 with a growing potential of 5.82%. Taiwan Over the Counter Drugs market accounts for 3.5% of the total Asia-Pacific OTC drugs market
Over the counter, the term mentions pharmaceuticals, which are bought across the counter without any need for a physician's prescription. OTC drugs are used to treat and prevent minor disorders. As a growing aging population, there is an increasing push to be able to license OTC medicines for the use of treatment of chronic conditions. The aging population (>65) accounts for 11.4% of the total population in Taiwan.
The government has reduced tax for the pharmaceutical industry to encourage many foreign multinational companies to invest in Taiwan. The government has recently made 13 prescription drugs available over the counter, making the purchase of the drugs more convenient. However, the government has also cut the price of drugs funded under national health programs.
Lower costs than prescription drugs drive the Taiwan OTC pharmaceutical market, growing preference for using OTC drugs for minor ailments, increased health care expenditure, Government policies like healthcare infrastructure and insurance system. Cost sensitivity of production is the major factor inhibiting the growth of the market.
This research report is segmented & sub-segmented the Taiwan OTC Drugs Market into the following categories:
Prominent companies leading Taiwan Over the Counter Drugs market are Eu Yan Sang International Ltd, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc, Merck Pte Ltd, Sunward Pharmaceutical Pte Ltd, Beacons Pharmaceuticals (Pte) Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com